

Improving Outcomes in Psychotic Disorders: Clozapine, LAIAs, VMAT2 Inhibitors for TD

Thursday, April 22, 2021 • 12 - 1 p.m. • Livestream

This series will have six sessions which occur every 4th Thursday, starting January 28, 2021 through June 24, 2021.

Registration

Please register with the following link:

<https://www.southernregionalahec.org/courses-and-events/65246>

By using this link, you are registering for the entire Alliance Health series. SR-AHEC will send a confirmation email with the webinar link before the start of each event. Please sign in to Zoom using your name and email associated with your MyAHEC account.

Target Audience

Prescribers of anti-psychotic medications (including psychiatrists and other physicians, nurse practitioners, and physician assistants) as well as all others interested are welcome to attend.

Description

The American Psychiatric Association released on September 1, 2020 a new set of evidence-based practice guidelines for the treatment of patients with schizophrenia with the goal of reducing the significant consequences the disorder has on individuals. In terms of medications, the new edition of the guideline emphasizes the circumstances in which use of clozapine or a long-acting injectable antipsychotic (LAIA) medication may improve outcomes. The availability of additional reversible inhibitors of the vesicular monoamine transporter 2 (VMAT2) is also new in this edition of the guideline for individuals who have moderate to severe or disabling tardive dyskinesia associated with antipsychotic therapy. By offering this virtual activity, we aim to increase the knowledge of the psychiatric prescribers in the areas of pharmacotherapy for psychotic disorders and, therefore, increase access to care and improve outcomes for our members.

Objectives

Upon completion of this workshop, participants will be able to:

- Describe the evidence and indications supporting Relprevv/olanzapine pamoate long-acting injectable antipsychotic use as a pharmacotherapeutic tool to increase its utilization and improve psychiatric outcomes including but not limited to symptom reduction.
- Explain the required monitoring of Relprevv, identification of Post-Delirium and Sedation Syndrome (PDSS), and actions to take during PDSS to facilitate comfort and increased use of this agent in appropriate clients.

Fee

FREE to attend

Agenda

12 – 1 p.m.

Removing the Reluctance From Olanzapine Pamoate Long-Acting Injectable

Melinda Asbury, MD, PhD

Assistant Professor, UNC School of Medicine

Medical Director, UNC Wake ACT Team

Psychiatrist, UNC Wake Encompass

Co-Investigator, NCPRC

Credit

AMA PRA Category 1 Credit™ – 1.0

Credit Statement: The Southern Regional AHEC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation: This activity has been planned and implemented in accordance with the Essentials and Standards of the North Carolina Medical Society (NCMS) through the joint providership of the Southern Regional AHEC and Alliance Health. The Southern Regional AHEC is accredited by the NCMS to provide continuing medical education for physicians.

Disclosure Statement: The Southern Regional AHEC adheres to ACCME Essential Areas and Policies regarding industry support of continuing medical education. Disclosure of faculty/planning committee members and commercial relationships will be made known at the activity. Speakers are also expected to openly disclose a discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

AAPA accepts certificate of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

ANCC and the North Carolina Board of Nursing accepts AMA PRA Category 1 Credits™ from the organizations accredited by the Accreditation Council for Continuing Medical Education (ACCME).

Contact

Courtney Masters, MSPH, SR-AHEC CME Director

courtney.masters@sr-ahec.org or (910) 678-7241